Literature DB >> 7053702

Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation.

L J Degroot, M Reilly.   

Abstract

We compared the utility of lower (30 mCi) and higher (50 to 60 mCi) doses of 131I used to ablate residual thyroid tissue after thyroidectomy for carcinoma. Whole body scans were done using 1 mCi 131I, 3 weeks after withdrawal of triiodothyronine. Patients had received ablation therapy within 3 days after scanning, and one or more subsequent scans were analyzed. Forty-eight patients were treated to ablate residual thyroid tissue that was presumed to be normal. Among 18 patients given the lower dose of 131I as outpatients, 15 had successful ablation and three needed a second administration; all 30 patients treated with the higher dose had successful ablation. Seventeen additional patients, presumed to have residual cancer, received 50 to 150 mCi; and six needed treatment. Although 1 dose of 50 to 60 mCi 131I provides more ablation, use of the usually effective 30-mCi dose for initial ablation is justified by the convenience of outpatient administration, the lower expense, and the lower whole-body radiation dose.

Entities:  

Mesh:

Year:  1982        PMID: 7053702     DOI: 10.7326/0003-4819-96-1-51

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

Review 1.  Management of thyroglobulin positive/whole-body scan negative: is Tg positive/131I therapy useful?

Authors:  I R McDougall
Journal:  J Endocrinol Invest       Date:  2001-03       Impact factor: 4.256

2.  Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer.

Authors:  V Oliynyk; O Epshtein; T Sovenko; M Tronko; R Elisei; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  2001-06       Impact factor: 4.256

Review 3.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

4.  Radioiodine-131 in differentiated thyroid cancer: a retrospective analysis of an uptake-related ablation strategy.

Authors:  Robbert B T Verkooijen; Marcel P M Stokkel; Jan W A Smit; Ernest K J Pauwels
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-14       Impact factor: 9.236

Review 5.  Drug therapy alternatives in the treatment of thyroid cancer.

Authors:  M J O'Doherty; A J Coakley
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 6.  Radionuclide therapy of the thyroid.

Authors:  S E Clarke
Journal:  Eur J Nucl Med       Date:  1991

7.  High or low dose radioiodine ablation of thyroid remnants?

Authors:  H Creutzig
Journal:  Eur J Nucl Med       Date:  1987

Review 8.  Radionuclide therapy revisited.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1991

9.  Rational management of differentiated thyroid cancer.

Authors:  Birendra Kishore Das; Biswa Mohan Biswal; Venkata Murali Krishna Bhavaraju
Journal:  Malays J Med Sci       Date:  2006-07

10.  Empiric Therapy with Low-Dose I-131 in Differentiated Cancer Thyroid: What is the Magic Number?

Authors:  Ajit S Shinto; K K Kamaleshwaran; Deepu K Shibu; K Vyshak; Joppy Antony
Journal:  World J Nucl Med       Date:  2013-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.